Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Int J Qual Stud Health Well-being ; 18(1): 2207926, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37166456

ABSTRACT

PURPOSE: To explore the opinions that baby boomers in Taiwan have about ageing, books written by members of this demographic were taken as the research object. METHODS: A total of 12 books were collected, and a content analysis was used to examine how baby boomers describe old age. RESULTS: Four themes were identified: 1) Greater mental maturity and strength, 2) a decline in the mastery of life, 3) risks related to encountering misfortune in the future, and 4) self-encouragement and vigilance. CONCLUSIONS: Members of the baby boomer generation in Taiwan believe that they can lead a good life in old age through their own efforts, and they tend to emphasize that they should make contributions in their old age. They especially want to show their abilities and dedication to family and maintain a good relationship with their children.


Subject(s)
Aging , Population Growth , Child , Humans , Taiwan
2.
Sci Rep ; 6: 32251, 2016 09 19.
Article in English | MEDLINE | ID: mdl-27642070

ABSTRACT

Phylogenetic clustering approaches can elucidate HIV transmission dynamics. Comparisons across countries are essential for evaluating public health policies. Here, we used a standardised approach to compare the UK HIV Drug Resistance Database and the Swiss HIV Cohort Study while maintaining data-protection requirements. Clusters were identified in subtype A1, B and C pol phylogenies. We generated degree distributions for each risk group and compared distributions between countries using Kolmogorov-Smirnov (KS) tests, Degree Distribution Quantification and Comparison (DDQC) and bootstrapping. We used logistic regression to predict cluster membership based on country, sampling date, risk group, ethnicity and sex. We analysed >8,000 Swiss and >30,000 UK subtype B sequences. At 4.5% genetic distance, the UK was more clustered and MSM and heterosexual degree distributions differed significantly by the KS test. The KS test is sensitive to variation in network scale, and jackknifing the UK MSM dataset to the size of the Swiss dataset removed the difference. Only heterosexuals varied based on the DDQC, due to UK male heterosexuals who clustered exclusively with MSM. Their removal eliminated this difference. In conclusion, the UK and Swiss HIV epidemics have similar underlying dynamics and observed differences in clustering are mainly due to different population sizes.


Subject(s)
Epidemics , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/genetics , Cluster Analysis , Female , HIV-1/classification , Heterosexuality/statistics & numerical data , Homosexuality, Male/statistics & numerical data , Humans , Logistic Models , Male , Phylogeny , Risk Factors , Switzerland/epidemiology , United Kingdom/epidemiology , pol Gene Products, Human Immunodeficiency Virus/classification , pol Gene Products, Human Immunodeficiency Virus/genetics
3.
Sci Rep ; 6: 27580, 2016 06 14.
Article in English | MEDLINE | ID: mdl-27297284

ABSTRACT

Targeting hard-to-reach/marginalized populations is essential for preventing HIV-transmission. A unique opportunity to identify such populations in Switzerland is provided by a database of all genotypic-resistance-tests from Switzerland, including both sequences from the Swiss HIV Cohort Study (SHCS) and non-cohort sequences. A phylogenetic tree was built using 11,127 SHCS and 2,875 Swiss non-SHCS sequences. Demographics were imputed for non-SHCS patients using a phylogenetic proximity approach. Factors associated with non-cohort outbreaks were determined using logistic regression. Non-B subtype (univariable odds-ratio (OR): 1.9; 95% confidence interval (CI): 1.8-2.1), female gender (OR: 1.6; 95% CI: 1.4-1.7), black ethnicity (OR: 1.9; 95% CI: 1.7-2.1) and heterosexual transmission group (OR:1.8; 95% CI: 1.6-2.0), were all associated with underrepresentation in the SHCS. We found 344 purely non-SHCS transmission clusters, however, these outbreaks were small (median 2, maximum 7 patients) with a strong overlap with the SHCS'. 65% of non-SHCS sequences were part of clusters composed of >= 50% SHCS sequences. Our data suggests that marginalized-populations are underrepresented in the SHCS. However, the limited size of outbreaks among non-SHCS patients in-care implies that no major HIV outbreak in Switzerland was missed by the SHCS surveillance. This study demonstrates the potential of sequence data to assess and extend the scope of infectious-disease surveillance.


Subject(s)
Drug Resistance, Viral/genetics , Genotype , HIV Infections/epidemiology , HIV-1/genetics , Substance Abuse, Intravenous/epidemiology , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Female , HIV Infections/drug therapy , HIV Infections/transmission , HIV Infections/virology , HIV-1/classification , HIV-1/isolation & purification , Heterosexuality , Homosexuality, Male , Humans , Male , Middle Aged , Molecular Typing , Multivariate Analysis , Phylogeny , Substance Abuse, Intravenous/drug therapy , Substance Abuse, Intravenous/virology , Switzerland/epidemiology
4.
J Infect Dis ; 214(3): 399-402, 2016 08 01.
Article in English | MEDLINE | ID: mdl-27130429

ABSTRACT

The prevalence of integrase strand transfer inhibitor (INSTI)-transmitted drug resistance (TDR) may increase with the increasing use of INSTIs. We analyzed the prevalence of INSTI TDR in the Swiss HIV Cohort Study (2008-2014). In 1 of 1316 drug-naive samples (0.1%), a major INSTI TDR mutation was detected. Prevalence was stable, although INSTIs were increasingly used. We showed that this is in contrast to the introduction of previous drug classes, in which more treatment failures with resistant strains occurred and TDR was observed more rapidly. We demonstrated on a population-level that it is possible to avoid TDR to a new drug class for years.


Subject(s)
Anti-HIV Agents/pharmacology , Disease Transmission, Infectious , Drug Resistance, Viral , HIV Infections/transmission , HIV Integrase/genetics , HIV/drug effects , HIV/genetics , Cohort Studies , Drug Utilization , HIV/isolation & purification , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/virology , HIV Integrase Inhibitors/therapeutic use , Humans , Prevalence , Switzerland/epidemiology
5.
Clin Infect Dis ; 62(10): 1310-1317, 2016 05 15.
Article in English | MEDLINE | ID: mdl-26962075

ABSTRACT

BACKGROUND: Drug resistance is a major barrier to successful antiretroviral treatment (ART). Therefore, it is important to monitor time trends at a population level. METHODS: We included 11 084 ART-experienced patients from the Swiss HIV Cohort Study (SHCS) between 1999 and 2013. The SHCS is highly representative and includes 72% of patients receiving ART in Switzerland. Drug resistance was defined as the presence of ≥1 major mutation in a genotypic resistance test. To estimate the prevalence of drug resistance, data for patients with no resistance test was imputed based on the patient's risk of harboring drug-resistant viruses. RESULTS: The emergence of new drug resistance mutations declined dramatically from 401 to 23 patients between 1999 and 2013. The upper estimated prevalence limit of drug resistance among ART-experienced patients decreased from 57.0% in 1999 to 37.1% in 2013. The prevalence of 3-class resistance decreased from 9.0% to 4.4% and was always <0.4% for patients who initiated ART after 2006. Most patients actively participating in the SHCS in 2013 with drug-resistant viruses initiated ART before 1999 (59.8%). Nevertheless, in 2013, 94.5% of patients who initiated ART before 1999 had good remaining treatment options based on Stanford algorithm. CONCLUSIONS: Human immunodeficiency virus type 1 drug resistance among ART-experienced patients in Switzerland is a well-controlled relic from the era before combination ART. Emergence of drug resistance can be virtually stopped with new potent therapies and close monitoring.


Subject(s)
Drug Resistance, Viral/genetics , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/drug effects , HIV-1/genetics , Adult , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Female , HIV Infections/drug therapy , Humans , Male , Middle Aged , Prevalence , Prospective Studies , Switzerland/epidemiology
6.
Clin Infect Dis ; 62(1): 115-122, 2016 Jan 01.
Article in English | MEDLINE | ID: mdl-26387084

ABSTRACT

BACKGROUND: Reducing the fraction of transmissions during recent human immunodeficiency virus (HIV) infection is essential for the population-level success of "treatment as prevention". METHODS: A phylogenetic tree was constructed with 19 604 Swiss sequences and 90 994 non-Swiss background sequences. Swiss transmission pairs were identified using 104 combinations of genetic distance (1%-2.5%) and bootstrap (50%-100%) thresholds, to examine the effect of those criteria. Monophyletic pairs were classified as recent or chronic transmission based on the time interval between estimated seroconversion dates. Logistic regression with adjustment for clinical and demographic characteristics was used to identify risk factors associated with transmission during recent or chronic infection. FINDINGS: Seroconversion dates were estimated for 4079 patients on the phylogeny, and comprised between 71 (distance, 1%; bootstrap, 100%) to 378 transmission pairs (distance, 2.5%; bootstrap, 50%). We found that 43.7% (range, 41%-56%) of the transmissions occurred during the first year of infection. Stricter phylogenetic definition of transmission pairs was associated with higher recent-phase transmission fraction. Chronic-phase viral load area under the curve (adjusted odds ratio, 3; 95% confidence interval, 1.64-5.48) and time to antiretroviral therapy (ART) start (adjusted odds ratio 1.4/y; 1.11-1.77) were associated with chronic-phase transmission as opposed to recent transmission. Importantly, at least 14% of the chronic-phase transmission events occurred after the transmitter had interrupted ART. CONCLUSIONS: We demonstrate a high fraction of transmission during recent HIV infection but also chronic transmissions after interruption of ART in Switzerland. Both represent key issues for treatment as prevention and underline the importance of early diagnosis and of early and continuous treatment.


Subject(s)
HIV Infections/epidemiology , HIV Infections/transmission , Adult , Algorithms , Cluster Analysis , Cohort Studies , Female , HIV Infections/drug therapy , HIV Infections/virology , HIV-1/genetics , Humans , Male , Phylogeny , Risk Factors , Switzerland/epidemiology
7.
J Antimicrob Chemother ; 70(12): 3323-31, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26362944

ABSTRACT

BACKGROUND: The most recommended NRTI combinations as first-line antiretroviral treatment for HIV-1 infection in resource-rich settings are tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. Efficacy studies of these combinations also considering pill numbers, dosing frequencies and ethnicities are rare. METHODS: We included patients starting first-line combination ART (cART) with or switching from first-line cART without treatment failure to tenofovir/emtricitabine, abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine plus efavirenz or nevirapine. Cox proportional hazards regression was used to investigate the effect of the different NRTI combinations on two primary outcomes: virological failure (VF) and emergence of NRTI resistance. Additionally, we performed a pill burden analysis and adjusted the model for pill number and dosing frequency. RESULTS: Failure events per treated patient for the four NRTI combinations were as follows: 19/1858 (tenofovir/emtricitabine), 9/387 (abacavir/lamivudine), 11/344 (tenofovir/lamivudine) and 45/1244 (zidovudine/lamivudine). Compared with tenofovir/emtricitabine, abacavir/lamivudine had an adjusted HR for having VF of 2.01 (95% CI 0.86-4.55), tenofovir/lamivudine 2.89 (1.22-6.88) and zidovudine/lamivudine 2.28 (1.01-5.14), whereas for the emergence of NRTI resistance abacavir/lamivudine had an HR of 1.17 (0.11-12.2), tenofovir/lamivudine 11.3 (2.34-55.3) and zidovudine/lamivudine 4.02 (0.78-20.7). Differences among regimens disappeared when models were additionally adjusted for pill burden. However, non-white patients compared with white patients and higher pill number per day were associated with increased risks of VF and emergence of NRTI resistance: HR of non-white ethnicity for VF was 2.85 (1.64-4.96) and for NRTI resistance 3.54 (1.20-10.4); HR of pill burden for VF was 1.41 (1.01-1.96) and for NRTI resistance 1.72 (0.97-3.02). CONCLUSIONS: Although VF and emergence of resistance was very low in the population studied, tenofovir/emtricitabine appears to be superior to abacavir/lamivudine, tenofovir/lamivudine and zidovudine/lamivudine. However, it is unclear whether these differences are due to the substances as such or to an association of tenofovir/emtricitabine regimens with lower pill burden.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , Nucleosides/therapeutic use , Nucleotides/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Adult , Drug Resistance, Viral , Female , HIV-1 , Humans , Male , Middle Aged , Switzerland , Treatment Failure
8.
Biostatistics ; 16(4): 713-26, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25979750

ABSTRACT

We introduce a new model called the observed time conjunctive Bayesian network (OT-CBN) that describes the accumulation of genetic events (mutations) under partial temporal ordering constraints. Unlike other CBN models, the OT-CBN model uses sampling time points of genotypes in addition to genotypes themselves to estimate model parameters. We developed an expectation-maximization algorithm to obtain approximate maximum likelihood estimates by accounting for this additional information. In a simulation study, we show that the OT-CBN model outperforms the continuous time CBN (CT-CBN) (Beerenwinkel and Sullivant, 2009. Markov models for accumulating mutations. Biometrika 96: (3), 645-661), which does not take into account individual sampling times for parameter estimation. We also show superiority of the OT-CBN model on several datasets of HIV drug resistance mutations extracted from the Swiss HIV Cohort Study database.


Subject(s)
Drug Resistance, Viral , HIV , Models, Genetic , Models, Statistical , Mutation Accumulation , Bayes Theorem , HIV/drug effects , HIV/genetics , Humans , Likelihood Functions
9.
PLoS Pathog ; 11(3): e1004722, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25798934

ABSTRACT

Transmission of drug-resistant pathogens presents an almost-universal challenge for fighting infectious diseases. Transmitted drug resistance mutations (TDRM) can persist in the absence of drugs for considerable time. It is generally believed that differential TDRM-persistence is caused, at least partially, by variations in TDRM-fitness-costs. However, in vivo epidemiological evidence for the impact of fitness costs on TDRM-persistence is rare. Here, we studied the persistence of TDRM in HIV-1 using longitudinally-sampled nucleotide sequences from the Swiss-HIV-Cohort-Study (SHCS). All treatment-naïve individuals with TDRM at baseline were included. Persistence of TDRM was quantified via reversion rates (RR) determined with interval-censored survival models. Fitness costs of TDRM were estimated in the genetic background in which they occurred using a previously published and validated machine-learning algorithm (based on in vitro replicative capacities) and were included in the survival models as explanatory variables. In 857 sequential samples from 168 treatment-naïve patients, 17 TDRM were analyzed. RR varied substantially and ranged from 174.0/100-person-years;CI=[51.4, 588.8] (for 184V) to 2.7/100-person-years;[0.7, 10.9] (for 215D). RR increased significantly with fitness cost (increase by 1.6[1.3,2.0] per standard deviation of fitness costs). When subdividing fitness costs into the average fitness cost of a given mutation and the deviation from the average fitness cost of a mutation in a given genetic background, we found that both components were significantly associated with reversion-rates. Our results show that the substantial variations of TDRM persistence in the absence of drugs are associated with fitness-cost differences both among mutations and among different genetic backgrounds for the same mutation.


Subject(s)
Drug Resistance, Viral/genetics , HIV Infections/genetics , HIV Infections/transmission , HIV-1/genetics , Models, Genetic , Mutation , Adult , Cohort Studies , Female , HIV-1/metabolism , Humans , Male
10.
J Infect Dis ; 212(1): 28-38, 2015 Jul 01.
Article in English | MEDLINE | ID: mdl-25576600

ABSTRACT

BACKGROUND: Transmitted human immunodeficiency virus type 1 (HIV) drug resistance (TDR) mutations are transmitted from nonresponding patients (defined as patients with no initial response to treatment and those with an initial response for whom treatment later failed) or from patients who are naive to treatment. Although the prevalence of drug resistance in patients who are not responding to treatment has declined in developed countries, the prevalence of TDR mutations has not. Mechanisms causing this paradox are poorly explored. METHODS: We included recently infected, treatment-naive patients with genotypic resistance tests performed ≤ 1 year after infection and before 2013. Potential risk factors for TDR mutations were analyzed using logistic regression. The association between the prevalence of TDR mutations and population viral load (PVL) among treated patients during 1997-2011 was estimated with Poisson regression for all TDR mutations and individually for the most frequent resistance mutations against each drug class (ie, M184V/L90M/K103N). RESULTS: We included 2421 recently infected, treatment-naive patients and 5399 patients with no response to treatment. The prevalence of TDR mutations fluctuated considerably over time. Two opposing developments could explain these fluctuations: generally continuous increases in the prevalence of TDR mutations (odds ratio, 1.13; P = .010), punctuated by sharp decreases in the prevalence when new drug classes were introduced. Overall, the prevalence of TDR mutations increased with decreasing PVL (rate ratio [RR], 0.91 per 1000 decrease in PVL; P = .033). Additionally, we observed that the transmitted high-fitness-cost mutation M184V was positively associated with the PVL of nonresponding patients carrying M184V (RR, 1.50 per 100 increase in PVL; P < .001). Such association was absent for K103N (RR, 1.00 per 100 increase in PVL; P = .99) and negative for L90M (RR, 0.75 per 100 increase in PVL; P = .022). CONCLUSIONS: Transmission of antiretroviral drug resistance is temporarily reduced by the introduction of new drug classes and driven by nonresponding and treatment-naive patients. These findings suggest a continuous need for new drugs, early detection/treatment of HIV-1 infection.


Subject(s)
Anti-HIV Agents/pharmacology , Drug Resistance, Viral , HIV Infections/epidemiology , HIV Infections/virology , HIV-1/drug effects , Mutation, Missense , Adult , Cohort Studies , Female , Genotype , HIV Infections/transmission , HIV-1/genetics , HIV-1/isolation & purification , Humans , Male , Prevalence , Prospective Studies
11.
Neoplasia ; 17(1): 89-100, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25622902

ABSTRACT

White spotting variant (Wv) mice are spontaneous mutants attributed to a point mutation in the c-Kit gene, which reduces the tyrosine kinase activity to around 1% and affects the development of melanocytes, mast cells, and germ cells. Homozygous mutant mice are sterile but can live nearly a normal life span. The female Wv mice have a greatly reduced ovarian germ cell and follicle reserve at birth, and the remaining follicles are largely depleted soon after the females reach reproductive stage at around 7 weeks of age. Consequently, ovarian epithelial tumors develop in 100% of Wv females by 3 to 4 months of age. These tumors, called tubular adenomas, are benign but can become invasive in older Wv mice. We tested if additional genetic mutation(s) could convert the benign ovarian epithelial tumors to malignant tumors by crossing the Wv mutant into the Trp53 knockout background. Surprisingly, we found that global deletion of Trp53 suppressed the development of ovarian tubular adenomas in Wv mice. The ovaries of Wv/Wv; Trp53 (-/-) mice were covered by a single layer of surface epithelium and lacked excessive epithelial proliferation. Rather, the ovaries contained a small number of follicles. The presence of ovarian follicles and granulosa cells, as indicated by Pgc7 and inhibin-alpha expression, correlated with the absence of epithelial lesions. A reduction of Pten gene dosage, as in Wv/Wv; Pten (+/-) mice, produced a similar, though less dramatic, phenotype. We conclude that deletion of Trp53 prolongs the survival of ovarian follicles in Wv mice and consequently prevents the proliferation of ovarian epithelial cells and development of ovarian tubular adenomas. The results suggest that various cell types within the ovary communicate and mutually modulate, and an intact tissue environment is required to ensure homeostasis of ovarian surface epithelial cells. Especially, the current finding emphasizes the importance of ovarian follicles in suppressing the hyperplastic growth of ovarian epithelial cells, dominating over the loss of p53.


Subject(s)
Gene Deletion , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Phenotype , Tumor Suppressor Protein p53/genetics , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Animals , Carcinoma/genetics , Carcinoma/metabolism , Carcinoma/pathology , Cell Proliferation , Disease Models, Animal , Female , Gene Dosage , Gene Expression , Inhibins/genetics , Inhibins/metabolism , Mice , Mice, Knockout , Models, Biological , Mutation , Nitric Oxide/biosynthesis , Ovarian Follicle/metabolism , Ovarian Follicle/pathology , Ovarian Neoplasms/metabolism , PTEN Phosphohydrolase/genetics , Proto-Oncogene Proteins c-kit/genetics , Signal Transduction
12.
Inform Prim Care ; 21(3): 142-51, 2014.
Article in English | MEDLINE | ID: mdl-25207618

ABSTRACT

BACKGROUND: Although the presence of an electronic health record (EHR) alone does not ensure high quality, efficient care, few studies have focused on the work of those charged with optimising use of existing EHR functionality. OBJECTIVE: To examine the approaches used and challenges perceived by analysts supporting the optimisation of primary care teams' EHR use at a large U.S. academic health care system. METHODS: A qualitative study was conducted. Optimisation analysts and their supervisor were interviewed and data were analysed for themes. RESULTS: Analysts needed to reconcile the tension created by organisational mandates focused on the standardisation of EHR processes with the primary care teams' demand for EHR customisation. They gained an understanding of health information technology (HIT) leadership's and primary care team's goals through attending meetings, reading meeting minutes and visiting with clinical teams. Within what was organisationally possible, EHR education could then be tailored to fit team needs. Major challenges were related to organisational attempts to standardise EHR use despite varied clinic contexts, personnel readiness and technical issues with the EHR platform. Forcing standardisation upon clinical needs that current EHR functionality could not satisfy was difficult. CONCLUSIONS: Dedicated optimisation analysts can add value to health systems through playing a mediating role between HIT leadership and care teams. Our findings imply that EHR optimisation should be performed with an in-depth understanding of the workflow, cognitive and interactional activities in primary care.


Subject(s)
Electronic Health Records/organization & administration , Patient Care Team , Primary Health Care/organization & administration , Electronic Health Records/standards , Humans , Interviews as Topic , Leadership , Qualitative Research , United States
13.
J Infect Dis ; 210(10): 1555-61, 2014 Nov 15.
Article in English | MEDLINE | ID: mdl-24943723

ABSTRACT

BACKGROUND: High-risk sexual behaviors have been suggested as drivers of the recent dramatic increase of sexually transmitted hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). METHODS: We assessed the association between the genetic bottleneck of HIV at transmission and the prevalence and incidence of HCV coinfection in HIV-infected MSM from the Swiss HIV Cohort Study (SHCS). As a proxy for the width of the transmission bottleneck, we used the fraction of ambiguous nucleotides detected by genotypic resistance tests sampled during early HIV infection. We defined a broad bottleneck as a fraction of ambiguous nucleotides exceeding a previously established threshold (0.5%). RESULTS: From the SHCS, we identified 671 MSM with available results of HCV serologic tests and with an HIV genotypic resistance test performed during early HIV infection. Of those, 161 (24.0%) exhibited a broad HIV transmission bottleneck, 38 (5.7%) had at least 1 positive HCV test result, and 26 (3.9%) had an incident HCV infection. Individuals with broad HIV transmission bottlenecks exhibited a 2-fold higher odds of having ever experienced an HCV coinfection (odds ratio, 2.2 [95% confidence interval {CI}, 1.1-4.3]) and a 3-fold higher hazard of having an incident HCV infection (hazard ratio, 3.0 [95% CI, 1.4-6.6]) than individuals with narrow HIV transmission bottlenecks. CONCLUSIONS: Our results indicate that the currently occurring sexual spread of HCV is focused on MSM who are prone to exhibit broad HIV transmission bottlenecks. This is consistent with an important role of high-risk behavior and mucosal barrier impairment in the transmission of HCV among MSM.


Subject(s)
Coinfection/epidemiology , HIV Infections/complications , Hepatitis C/epidemiology , Hepatitis C/transmission , Homosexuality, Male , Adult , Cohort Studies , Humans , Incidence , Male , Prevalence , Risk Assessment , Switzerland/epidemiology
14.
Clin Infect Dis ; 58(2): 285-94, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24145874

ABSTRACT

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) can compromise antiretroviral therapy (ART) and thus represents an important public health concern. Typically, sources of TDR remain unknown, but they can be characterized with molecular epidemiologic approaches. We used the highly representative Swiss HIV Cohort Study (SHCS) and linked drug resistance database (SHCS-DRDB) to analyze sources of TDR. METHODS: ART-naive men who have sex with men with infection date estimates between 1996 and 2009 were chosen for surveillance of TDR in HIV-1 subtype B (N = 1674), as the SHCS-DRDB contains pre-ART genotypic resistance tests for >69% of this surveillance population. A phylogeny was inferred using pol sequences from surveillance patients and all subtype B sequences from the SHCS-DRDB (6934 additional patients). Potential sources of TDR were identified based on phylogenetic clustering, shared resistance mutations, genetic distance, and estimated infection dates. RESULTS: One hundred forty of 1674 (8.4%) surveillance patients carried virus with TDR; 86 of 140 (61.4%) were assigned to clusters. Potential sources of TDR were found for 50 of 86 (58.1%) of these patients. ART-naive patients constitute 56 of 66 (84.8%) potential sources and were significantly overrepresented among sources (odds ratio, 6.43 [95% confidence interval, 3.22-12.82]; P < .001). Particularly large transmission clusters were observed for the L90M mutation, and the spread of L90M continued even after the near cessation of antiretroviral use selecting for that mutation. Three clusters showed evidence of reversion of K103N or T215Y/F. CONCLUSIONS: Many individuals harboring viral TDR belonged to transmission clusters with other Swiss patients, indicating substantial domestic transmission of TDR in Switzerland. Most TDR in clusters could be linked to sources, indicating good surveillance of TDR in the SHCS-DRDB. Most TDR sources were ART naive. This, and the presence of long TDR transmission chains, suggests that resistance mutations are frequently transmitted among untreated individuals, highlighting the importance of early diagnosis and treatment.


Subject(s)
Anti-HIV Agents/pharmacology , Drug Resistance, Viral , HIV Infections/transmission , HIV-1/drug effects , Adult , Anti-HIV Agents/therapeutic use , Cluster Analysis , Cohort Studies , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV Infections/virology , Homosexuality, Male , Humans , Male , Middle Aged , Molecular Epidemiology , Phylogeny , Sequence Homology , Switzerland/epidemiology , Young Adult , pol Gene Products, Human Immunodeficiency Virus/genetics
15.
J Am Chem Soc ; 135(50): 18758-61, 2013 Dec 18.
Article in English | MEDLINE | ID: mdl-24289743

ABSTRACT

The reversible transformations [(Bim)3Fe(κ(2)-O2N)][BF4] (3) <-> [(Bim)3Fe(NO)(κ(1)-ONO)][BF4]2 (4) were demonstrated and characterized. Transformation of O,O-nitrito-containing complex 3 into [(Bim)3Fe(µ-O)(µ-OAc)Fe(Bim)3](3+) (5) along with the release of NO and H2O triggered by 1 equiv of AcOH implicates that nitrite-to-nitric oxide conversion occurs, in contrast to two protons needed to trigger nitrite reduction producing NO observed in the protonation of [Fe(II)-nitro] complexes.


Subject(s)
Ferrous Compounds/chemistry , Hemerythrin/chemistry , Hemoglobins/chemistry , Nitric Oxide/chemistry , Nitrite Reductases/chemistry , Nitrites/chemistry , Spectrum Analysis/methods
16.
Biol Reprod ; 89(4): 103, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23966321

ABSTRACT

Menopause is the permanent cessation of menstruation that results from depletion of ovarian germ cells and follicles. Although most animals experience reproductive senescence, the mechanisms differ from that in women, who may live more than one-third of their lives after menopause and consequently face the risk of a number of menopause-associated health problems. Understanding factors that influence ovarian aging may provide strategies to delay or alleviate physiological alterations that take place in postmenopausal women. The germ cell-deficient Wv mice recapitulate follicle loss, prolong postreproductive lifespan, and model many physiological changes that take place in postmenopausal women. Here, using genetic and pharmacological approaches, we found that inhibition of cyclooxygenase-1 but not cyclooxygenase-2 in Wv mice delays germ cell depletion and preserves ovarian follicles. Cyclooxygenase-1 inhibition slows down follicle maturation at the conversion of primary to secondary follicles and prolongs postnatal ovarian follicle lifespan. The current study suggests that inhibition of cyclooxygenase-1 may be able to delay ovarian aging and modulate menopausal timing.


Subject(s)
Aging , Cyclooxygenase Inhibitors/therapeutic use , Membrane Proteins/antagonists & inhibitors , Menopause/drug effects , Ovarian Follicle/drug effects , Primary Ovarian Insufficiency/prevention & control , Animals , Celecoxib , Crosses, Genetic , Cyclooxygenase 1/genetics , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/chemistry , Cyclooxygenase 2/genetics , Cyclooxygenase 2/metabolism , Cyclooxygenase 2 Inhibitors/therapeutic use , Female , Indomethacin/therapeutic use , Membrane Proteins/genetics , Membrane Proteins/metabolism , Menopause/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , Ovarian Follicle/growth & development , Ovarian Follicle/metabolism , Ovarian Follicle/pathology , Primary Ovarian Insufficiency/metabolism , Primary Ovarian Insufficiency/pathology , Pyrazoles/therapeutic use , Random Allocation , Sexual Development/drug effects , Sulfonamides/therapeutic use
17.
Menopause ; 19(5): 588-96, 2012 May.
Article in English | MEDLINE | ID: mdl-22228319

ABSTRACT

OBJECTIVE: Menopause is a unique phenomenon in modern women, as most mammalian species possess a reproductive period comparable with their life span. Menopause is caused by the depletion of germ cell-containing ovarian follicles and in laboratory studies is usually modeled in animals in which the ovarian function is removed through ovariectomy or chemical poisoning of the germ cells. Our objective was to explore and characterize the white spotting variant (Wv) mice that have reduced ovarian germ cell abundance, a result of a point mutation in the c-kit gene that decreases kinase activity, as a genetic model for use in menopause studies. METHODS: Physiological and morphological features associated with menopause were determined in female Wv/Wv mice compared with age-matched wildtype controls. Immunohistochemistry was used to evaluate the presence and number of follicles in paraffin-embedded ovaries. Bone density and body composition were evaluated using the PIXImus x-ray densitometer, and lipids, calcium, and hormone levels were determined in serum using antigen-specific enzyme immunoassays. Heart and body weight were measured, and cardiac function was evaluated using transthoracic echocardiography. RESULTS: The ovaries of the Wv/Wv females have a greatly reduced number of normal germ cells at birth compared with wildtype mice. The remaining follicles are depleted by around 2 months, and the ovaries develop benign epithelial lesions that resemble morphological changes that occur during ovarian aging, whereas a normal mouse ovary has numerous follicles at all stages of development and retains some follicles even in advanced age. Wv mice have elevated plasma gonadotropins and reduced estrogen and progesterone levels, a significant reduction in bone mass density, and elevated serum cholesterol and lipoprotein levels. Moreover, the Wv female mice have enlarged hearts and reduced cardiac function. CONCLUSIONS: The reduction of c-kit activity in Wv mice leads to a substantially diminished follicular endowment in newborn mice and premature depletion of follicles in young mice, although mutant females have a normal life span after cessation of ovarian function. The Wv female mice exhibit consistent physiological changes that resemble common features of postmenopausal women. These alterations include follicle depletion, morphological aging of the ovary, altered serum levels of cholesterol, gonadotropins and steroid hormones, decreased bone density, and reduced cardiac function. These changes were not observed in male mice, either age-matched male Wv/Wv or wildtype mice, and are improbably caused by global loss of c-kit function. The Wv mouse may be a genetic, intact-ovary model that mimics closely the phenotypes of human menopause to be used for further studies to understand the mechanisms of menopausal biology.


Subject(s)
Aging , Menopause/physiology , Models, Animal , Myocardium/pathology , Ovary/physiology , Animals , Body Composition , Bone Density , Cholesterol/blood , Estrogens/blood , Female , Gonadotropins/blood , Heart/physiopathology , Humans , Lipoproteins/blood , Menopause/blood , Mice , Organ Size , Ovarian Follicle , Progesterone/blood , Proto-Oncogene Proteins c-kit/genetics
18.
Am J Pathol ; 170(4): 1325-36, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17392171

ABSTRACT

Menopausal ovaries undergo morphological changes, known as ovarian aging, which are implicated in the high incidence of ovarian cancer occurring during the perimenopausal and immediate postmenopausal periods. The germ cell-deficient Wv mice recapitulate these postmenopausal alterations in ovarian morphology and develop tubular adenomas. We demonstrate that a reduction of cyclooxygenase 2 gene dosage rescued the ovarian aging phenotype of the Wv mice, whereas homozygous deletion was accompanied by a compensatory increase in ovarian cyclooxygenase 1 expression and prostaglandin E(2) synthesis. Cyclooxygenase inhibitors also reduced the tumor phenotype in a preliminary study. These findings suggest that increased cyclooxygenase activity contributes to the preneoplastic morphological changes of the ovarian surface epithelium, which can be reversed by a reduction of gene dosage achieved by either genetic or pharmacological approaches.


Subject(s)
Aging/pathology , Cyclooxygenase 2/metabolism , Ovarian Neoplasms/pathology , Ovary/pathology , Adenoma/genetics , Adenoma/metabolism , Adenoma/pathology , Animals , Blotting, Western , Celecoxib , Cell Transformation, Neoplastic/drug effects , Cyclooxygenase 2/deficiency , Cyclooxygenase 2/genetics , Cyclooxygenase Inhibitors/administration & dosage , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/metabolism , Epithelium/metabolism , Epithelium/pathology , Female , Gene Dosage , Heterozygote , Homozygote , Humans , Inbreeding , Indomethacin/administration & dosage , Indomethacin/pharmacology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Ovary/drug effects , Ovary/metabolism , Phenotype , Pyrazoles/administration & dosage , Pyrazoles/pharmacology , Sulfonamides/administration & dosage , Sulfonamides/pharmacology
19.
Mol Carcinog ; 46(2): 130-43, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17131304

ABSTRACT

The role for matrix metalloproteinases (MMPs) in tumor cells invasion and metastasis is well established, and expression of MMPs is recognized as an indication of tumor cell malignancy. Previous studies suggest that the degradation of the basement membrane is a crucial early step in epithelial transformation and ovarian tumorigenesis. Thus, MMPs may also express and exert a role in preneoplastic lesions of ovarian tissues. We investigated the expression of the major metalloproteinases, gelatinase A, 72 kDa type IV collagenase (MMP-2), and gelatinase B, 92 kDa type IV collagenase (MMP-9), and the presence of basement membrane in ovarian tumors and tissues from prophylactic oophorectomies using immunostaining. MMP expression was also characterized in a panel of ovarian cancer cell lines and several nontumorigenic ovarian surface epithelial primary cells by zymography, Northern, and Western blots. We found, surprisingly, that MMP-2 and MMP-9 are expressed more frequently in early lesions than in established carcinomas. No correlation was found between the expression of MMPs and tumor grades or stages. In preneoplastic lesions, MMP-2 or MMP-9 expression often associates with the absence of basement membrane and morphological alterations. MMP-2 is often expressed in nontumorigenic ovarian surface epithelial cells but reduced or absent in cancer cells. Thus, we conclude that MMPs expression does not correlate with the malignancy of ovarian epithelial cells as generally thought. Rather, increased metalloproteinase expression is an early event in ovarian tumorigenesis and associates with the loss of epithelial basement membrane and morphological transformation. We propose that the increased MMP activity is an etiological factor for ovarian cancer risk. We found that MMPs expression does not correlate with the malignancy of ovarian epithelial cells as generally thought. Rather, increased metalloproteinase expression is an early event in ovarian tumorigenesis. The finding suggests roles of MMP in tumor initiation in addition to invasion, and may impact on the strategy for use of MMP inhibitors in cancer prevention.


Subject(s)
Cell Transformation, Neoplastic , Matrix Metalloproteinases/metabolism , Ovarian Neoplasms/enzymology , Blotting, Northern , Blotting, Western , Cell Line, Transformed , Female , Humans , Immunohistochemistry , Ovarian Neoplasms/pathology , RNA, Small Interfering , Tissue Array Analysis
20.
Oncogene ; 24(54): 7991-8002, 2005 Dec 01.
Article in English | MEDLINE | ID: mdl-16044148

ABSTRACT

Cyclooxygenase 2 (COX-2) is often found overexpressed in cancer and is thought to have a role in carcinogenic promotion, and thus is a target for therapeutic intervention. Here, we investigated the regulation of COX-2 expression in normal and cancer ovarian surface epithelial cells. Tumor necrosis factor alpha (TNF-alpha) is a potent inducer of COX-2 expression in the ovarian surface epithelium and this regulation is a critical step in ovulation. We observed that TNF-alpha stimulated COX-2 expression in human primary and immortalized epithelial (HIO) cell lines. The stimulation was suppressed by inhibitors of several signaling pathways, indicating the collaboration of TNF-alpha-activated signaling pathways mediates the regulation of COX-2 expression. In five ovarian cancer cell lines analysed, four did not express detectable COX-2 and TNF-alpha failed to elicit COX-2 expression. In NIH:OVCAR-5, the only ovarian cancer cell line expressing COX-2, signal pathway inhibitors no longer affected TNF-alpha-induced COX-2 expression. Thus, we conclude that TNF-alpha mediated signaling is uncoupled from the modulation of COX-2 expression in ovarian cancer. The loss of COX-2 expression was also observed to associate closely with epithelial neoplastic morphological transformation. The frequent loss of COX-2 expression suggests in ovarian cancer, unlike in other epithelial cancers, COX-2 expression does not contribute to ovarian cancer malignancy.


Subject(s)
Cyclooxygenase 2/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Membrane Proteins/metabolism , Ovarian Neoplasms/enzymology , Ovarian Neoplasms/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Blotting, Western , Cell Line, Transformed , Cell Line, Tumor , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunohistochemistry , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...